Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase

Hongchuan Jin, Tobias Sperka, Peter Herrlich and Helen Morrison ()
Additional contact information
Hongchuan Jin: Leibniz Institute of Age Research–Fritz-Lipmann-Institute
Tobias Sperka: Leibniz Institute of Age Research–Fritz-Lipmann-Institute
Peter Herrlich: Leibniz Institute of Age Research–Fritz-Lipmann-Institute
Helen Morrison: Leibniz Institute of Age Research–Fritz-Lipmann-Institute

Nature, 2006, vol. 442, issue 7102, 576-579

Abstract: Tumour-causing cascade The phosphatase that activates the Merlin tumour suppressor (also known as neurofibromatosis 2) has been identified. It's a myosin phosphatase that is inhibited by the endogenous inhibitor CPI-17, which is often upregulated in human tumours and may contribute to the development of cancer by inactivating Merlin. Taken together, these findings point to a novel cascade of tumour suppressors whose action can be abolished in at least two ways, by mutation (NF2) or upregulation of the putative novel oncogene, CPI-17.

Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature04856 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:442:y:2006:i:7102:d:10.1038_nature04856

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature04856

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().